UNCY - Unicycive stock soars 25% as kidney drug UNI-494 shows promise in preclinical study in rats

• Unicycive Therapeutics ( NASDAQ: UNCY ) said treatment with UNI-494 showed a statistically significant reduction of a key biomarker of kidney injury in a preclinical study of an animal model of acute kidney injury (AKI).
• The company evaluated the effect of UNI-494 on ischemia-reperfusion induced acute kidney injury (IR-AKI) in rats.
• Unicycive said UNI-494 was given orally 1-hour before the induction of ischemia, and kidney function was monitored by measuring urinary creatinine, total urinary albumin, and ?-2 microglobulin (?-2 MG).
• Treatment of the animals with the higher dose of UNI-494 resulted in a statistically significant reduction of ?-2 MG levels in urine, the company said in a Sept. 7 press release.
• "We remain on track to file a regulatory submission by the end of 2022 that will allow us to initiate our Phase 1 study with UNI-494," said Unicycive CEO Shalabh Gupta.
• UNCY +25.35% to $0.89 premarket Sept. 7

For further details see: